Scopolamine is an alkaloid used as an anesthetic, anticholinergic, and antispasmodic drug. It is extracted from plants of the nightshade family, primarily Datura and Atropa belladonna. Scopolamine is primarily used in the treatment of motion sickness and postoperative nausea and vomiting. It works by blocking the neurotransmitter acetylcholine in the brain and other parasympathetic nervous system receptors. Scopolamine is often combined with other medications used for general anesthesia. It is also used to treat excessive gastrointestinal secretions and Parkinson’s disease. The global scopolamine API market is also driven by the increasing prevalence of neuropathic pain. Neuropathic pain affects millions of people worldwide and is often difficult to treat. Scopolamine has shown efficacy in reducing symptoms of neuropathic pain such as burning sensation, shooting pains, and electric shock-like pains.
The global Scopolamine API Market is estimated to be valued at US$ 308.49 Mn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The scopolamine API market is expected to be flourished by the increasing adoption of scopolamine in neuropathic pain treatment. Neuropathic pain affects millions of people globally each year and conventional pain management therapies often provide inadequate relief. Recent studies have demonstrated the potential of scopolamine in reducing symptoms of neuropathic pain such as thermal allodynia, mechanical allodynia, and spontaneous pain. The analgesic effects of scopolamine are mediated through its antagonistic effects on muscarinic acetylcholine receptors in the central nervous system. As there exists significant unmet needs for more effective neuropathic pain management options, the analgesic properties of scopolamine are expected to drive increased adoption and overall growth of the scopolamine API market over the forecast period.
Another major driver for the market growth is the rising prevalence of Parkinson’s disease globally. Scopolamine is an effective treatment for reducing excessive salivation and drooling, which are common symptoms of Parkinson’s disease. With the aging global population and increasing prevalence of Parkinson’s disease, demand for scopolamine API from Parkinson’s disease therapeutics segment is expected to increase considerably during the forecast period.
The global scopolamine API market is dominated by the hyoscine butylbromide segment, which accounts for around 60% of the total market share. Hyoscine butylbromide is primarily used to treat gastrointestinal spasms, abdominal pain, and motion sickness. It is preferred over other segments like hyoscine hydrobromide due to its longer duration of action and fewer side effects.
Political: Regulations regarding the production and sales of scopolamine API are well defined by agencies like WHO and FDA to ensure quality and safety. However, political instability in some regions can disrupt supply chains.
Economic: Rising healthcare spending across developed and developing nations is driving market growth. However, economic slowdowns can negatively impact the market.
Social: Increasing incidence of gastrointestinal diseases and motion sickness worldwide is resulting in higher social acceptability and demand for effective drugs using scopolamine API.
Technological: Advancements in pharmaceutical manufacturing technologies are helping improve the quality, efficacy, and safety of drugs using scopolamine API. Automation is also reducing production costs.
The global Scopolamine API Market Growth is expected to witness high growth at a CAGR of around 10% during the forecast period of 2023 to 2030. The global Scopolamine API Market is estimated to be valued at US$ 308.49 Mn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030.
The Asia Pacific region is projected to grow the fastest during the forecast period. This can be attributed to factors like the rising prevalence of gastrointestinal and motion sickness disorders, growing health awareness, increasing income levels, expanding healthcare infrastructure and services, and strong presence of generic drug manufacturers in the region.
Key players operating in the scopolamine API market are Daikin Industries Limited, Viessmann Group, NIBE Group, Danfoss Group Global, Stiebel Eltron Group, Mitsubishi Electric Corporation, United Technologies Corporation, Panasonic Corporation, Glen Dimplex Group, and The Bosch Group.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it